Press Releases

Filter by Category

All Blogs Presentations Press Releases Publications Videos

Filter by Program

Filter by Publish Date

C-Path Appoints Two New Members to Board of Directors

TUCSON, Ariz., April 30, 2020 — Tucson-based Critical Path Institute (C-Path) today announced the appointment of two new

C-Path ePRO Consortium and PRO Consortium Announce COVID-19 Risk Assessment and Mitigation Strategies

Recommendations provided for sponsors and eCOA providers to facilitate the continued collection of PRO data in clinical trials. &n

C-Path Receives Letter of Support from EMA on Type 1 Diabetes Biomarker Initiative

TUCSON, Ariz., April 28, 2020 — The Critical Path Institute (C-Path) today announced that its Type 1 Diabetes (T1D

C-Path Awarded FDA Contract to Enhance the Assessment of Clinical Outcomes in Pediatric Asthma Treatment Trials

Resulting novel drug development tools will support patient-focused drug development for children with asthma TUCSON

C-Path Receives FDA Grant to Establish Rare Disease Clinical Outcome Assessment Consortium

TUCSON, Ariz., March 19, 2020 — The U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Res

C-Path and Lundbeck Announce a Data Sharing Collaboration to Enable Development of Advanced Drug Development Tools in Alzheimer’s Disease

TUCSON, Ariz., March 18, 2020 — The Critical Path Institute (C-Path) and H. Lundbeck A/S (Lundbeck) are proud to a

C-Path to Lead Multi-Stakeholder Engagement on FDA’s Proposed Novel Framework to Enhance the Pediatric Medical Device Ecosystem

TUCSON, Ariz., March 17, 2020 — The Critical Path Institute (C-Path) today announced it has been awarded a grant to condu

C-Path Appoints Dr. Klaus Romero as Chief Science Officer

TUCSON, Ariz., March 12, 2020 — The Critical Path Institute (C-Path) today announced the appointment of Klaus Rome

C-Path Selects Experienced Neuroscientist to Lead Alzheimer’s Consortium

TUCSON, Ariz., March 12, 2020 — The Critical Path Institute (C-Path) today announced it has named Sudhir Sivakumar

ERA4TB, an International Consortium to Accelerate the Development of Comprehensive Treatments Against Tuberculosis

C-Path, Ltd. and more than 30 partners from 13 countries participate in the ERA4TB project. The ERA4TB (European Regimen Ac

Previous1516 17...25 Next